Hepatic Impairment Clinical Trials in San Antonio, Texas
13 recruitingSan Antonio, Texas
Showing 1–13 of 13 trials
Recruiting
Phase 1
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
Healthy VolunteersHepatic Impairment
Bristol-Myers Squibb24 enrolled3 locationsNCT07248839
Recruiting
Phase 1
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting
Phase 1
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 1
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
Severe Hepatic ImpairmentNormal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)20 enrolled3 locationsNCT07250633
Recruiting
Phase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Hepatic Impairment
AstraZeneca28 enrolled4 locationsNCT07546760
Recruiting
Phase 1
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Moderate Hepatic Impairment
AstraZeneca20 enrolled2 locationsNCT07343960
Recruiting
Phase 1
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
HealthyHepatic Impairment
Boehringer Ingelheim44 enrolled1 locationNCT07486102
Recruiting
Phase 1
Radiprodil in Participants With Hepatic Impairment
Hepatic Impairment
GRIN Therapeutics, Inc.40 enrolled2 locationsNCT07457229
Recruiting
Phase 1
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
HealthyHepatic Impairment
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany32 enrolled3 locationsNCT06997276
Recruiting
Phase 1
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
HealthyHepatic Impairment
Merck Sharp & Dohme LLC58 enrolled3 locationsNCT07219550
Recruiting
Phase 1
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Hepatic Impairment (HI)
Merck Sharp & Dohme LLC32 enrolled3 locationsNCT06442436
Recruiting
Phase 1
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Moderate Hepatic ImpairmentHepatic Impairment
Exelixis20 enrolled2 locationsNCT06962332
Recruiting
Phase 1
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
CirrhosisHepatic Impairment
Vir Biotechnology, Inc.144 enrolled5 locationsNCT05484206